aTyr Pharma Announces First Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trials in Pulmonary Sarcoidosis and COVID-19
May 12, 2020 16:05 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 12, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma to Webcast Conference Call Reporting First Quarter 2020 Financial Results
May 06, 2020 08:03 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Announces Publication of Two Abstracts in American Journal of Respiratory and Critical Care Medicine
May 05, 2020 08:03 ET
|
aTyr Pharma, Inc.
Abstracts originally accepted for presentation at the 2020 American Thoracic Society (ATS) International Conference Findings confirm that aTyr’s lead clinical candidate, ATYR1923, selectively binds...
aTyr Pharma Announces Phase 2 Study of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Following FDA Acceptance of IND Application
April 21, 2020 08:30 ET
|
aTyr Pharma, Inc.
SAN DIEGO, April 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma Announces Fourth Quarter and Full Year 2019 Results and Provides Corporate Update
March 26, 2020 16:01 ET
|
aTyr Pharma, Inc.
Company to host conference call and webcast today at 5:00 p.m. EDT / 2:00 p.m. PDT SAN DIEGO, March 26, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged...
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Government Grant to Fund Bispecific Antibody Development Platform
March 24, 2020 08:30 ET
|
aTyr Pharma, Inc.
Grant awarded by the Hong Kong Government's Innovation and Technology Commission under the Partnership Research Program Two-year project will initially focus on development of new bi-specific...
aTyr Pharma to Announce Fourth Quarter and Full Year End 2019 Financial Results on March 26th
March 19, 2020 16:05 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 19, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
Leading Cancer Researcher Dr. Arthur M. Mercurio Joins aTyr as Scientific Advisor
March 17, 2020 08:30 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 17, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma Announces Exercise and Closing of Over-Allotment Option in Public Offering
March 10, 2020 08:30 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
March 03, 2020 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 03, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...